Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation and Management of Nonculprit Lesions in STEMI.
Thim T, van der Hoeven NW, Musto C, Nijveldt R, Götberg M, Engstrøm T, Smits PC, Oldroyd KG, Gershlick AH, Escaned J, Baptista SB, Raposo L, van Royen N, Maeng M. Thim T, et al. Among authors: smits pc. JACC Cardiovasc Interv. 2020 May 25;13(10):1145-1154. doi: 10.1016/j.jcin.2020.02.030. JACC Cardiovasc Interv. 2020. PMID: 32438985 Free article. Review.
Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y, Girasis C, Piazza N, Garcia-Garcia HM, Kukreja N, Garg S, Eindhoven J, Cheng JM, Valgimigli M, van Domburg R, Serruys PW; Interventional Cardiologists at Thoraxcenter 2000-2005. Onuma Y, et al. JACC Cardiovasc Interv. 2010 Jun;3(6):584-94. doi: 10.1016/j.jcin.2010.03.017. JACC Cardiovasc Interv. 2010. PMID: 20630451 Free article.
Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
Gomez-Lara J, Brugaletta S, Farooq V, van Geuns RJ, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Morel MA, Dorange C, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Gomez-Lara J, et al. Among authors: smits pc. JACC Cardiovasc Interv. 2011 Jul;4(7):789-99. doi: 10.1016/j.jcin.2011.04.009. JACC Cardiovasc Interv. 2011. PMID: 21777888 Free article. Clinical Trial.
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Claessen BE, et al. Among authors: smits pc. JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016. JACC Cardiovasc Interv. 2011. PMID: 22115661 Free article.
Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, Thuesen L, McClean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Chevalier B, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Gomez-Lara J, et al. Among authors: smits pc. JACC Cardiovasc Interv. 2011 Dec;4(12):1271-80. doi: 10.1016/j.jcin.2011.08.016. JACC Cardiovasc Interv. 2011. PMID: 22192368 Free article. Clinical Trial.
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S, Gomez-Lara J, Serruys PW, Farooq V, van Geuns RJ, Thuesen L, Dudek D, Koolen J, Chevalier B, McClean D, Windecker S, Smits PC, de Bruyne B, Whitbourn R, Meredith I, van Domburg RT, Sihan K, de Winter S, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM, Ormiston JA, Bruining N. Brugaletta S, et al. Among authors: smits pc. JACC Cardiovasc Interv. 2011 Dec;4(12):1281-9. doi: 10.1016/j.jcin.2011.08.014. JACC Cardiovasc Interv. 2011. PMID: 22192369 Free article. Clinical Trial.
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Onuma Y, et al. Among authors: smits pc. JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016. JACC Cardiovasc Interv. 2014. PMID: 25523532 Free article. Clinical Trial.
Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).
Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, van Mieghem C, van de Ent M. Smits PC, et al. JACC Cardiovasc Interv. 2015 Aug 17;8(9):1157-1165. doi: 10.1016/j.jcin.2015.03.028. Epub 2015 Jul 22. JACC Cardiovasc Interv. 2015. PMID: 26210806 Free article. Clinical Trial.
245 results